AI-Powered COPD Research

COPD is a progressive lung disease affecting 16 million Americans. AI agents research lung regeneration, anti-inflammatory biologics, and novel bronchodilator strategies.

Standard of Care

Inhaled bronchodilators (LABA + LAMA), inhaled corticosteroids (eosinophilic phenotype), triple therapy (ICS/LABA/LAMA), pulmonary rehabilitation, supplemental oxygen, smoking cessation.

Prevalence

~16 million diagnosed Americans (millions more undiagnosed). 3rd leading cause of death worldwide. ~120,000 US deaths/year.

Key Biomarkers

• FEV1/FVC ratio (<0.70)
• Blood eosinophil count
• DLCO (diffusion capacity)
• CT emphysema scoring
• Fibrinogen, CRP (systemic inflammation)

Emerging Research

Biologics for eosinophilic COPD (dupilumab, benralizumab showing benefit in BOREAS/NOTUS trials). Ensifentrine (dual PDE3/PDE4 inhibitor) — first novel COPD mechanism in decades. Lung volume reduction coils/valves. Lung stem cell therapy for regeneration. Anti-IL-33 (itepekimab) for COPD prevention.

Frequently Asked Questions

Can biologics help COPD?

Yes — dupilumab (anti-IL-4/IL-13) reduced COPD exacerbations by 30% in patients with elevated eosinophils (BOREAS trial). This mirrors the biologic revolution in asthma. Patient selection based on eosinophil count and exacerbation history is key. Multiple biologics are now in COPD trials.

Can damaged lungs regenerate?

The lungs have limited but real regenerative capacity. Distal lung progenitor cells (alveolar type 2 cells) can regenerate alveoli. Research focuses on activating endogenous stem cells, transplanting lung organoids, and using growth factors to stimulate repair. Clinical applications are still early-stage but advancing rapidly.